Open an account

Neuronetics

STIM · NASDAQ

$1.98+$0.07 (+3.66%)TodayMarket closed ·
Prev close $1.91

About STIM

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 658 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.

Employees
658
Headquarters
Malvern, Pennsylvania
Listed
Jun 28, 2018
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
neurostar.com

STIM key statistics

Market cap
150.87M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
759.90K
Volume
603.22K
Open price
$1.88
High today
$2.02
Low today
$1.88
52 Week high
$3.44
52 Week low
$0.80

Neuronetics (STIM) at a glance

Neuronetics (STIM) last traded at $1.98, with a market cap of 150.87M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.88 and $2.02. The current price is 5.5% above the day's low and 2.0% below its high.

Volume so far is 603.22K shares, below the average of 759.90K shares a day.

Over the past year Neuronetics has ranged from $0.80 to $3.44, and now sits 45% of the way up that range.

Neuronetics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.04 per share against an estimate of -$0.125.

The average analyst price target is $5.86, 196.2% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $5.86
Low
$5.05
Now
$1.98
High
$7.35

STIM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 30.4% on average.

  1. Q3 FY24: reported -$0.44 per share against an estimate of -$0.2346
  2. Q4 FY24: reported -$0.33 per share against an estimate of -$0.2142
  3. Q1 FY25: reported -$0.21 per share against an estimate of -$0.1275
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.0782
  5. Q3 FY25: reported -$0.13 per share against an estimate of -$0.1292
  6. Q4 FY25: reported -$0.10 per share against an estimate of -$0.1088
  7. Q1 FY26: reported -$0.15 per share against an estimate of -$0.1768
  8. Q2 FY26: reported -$0.04 per share against an estimate of -$0.125

STIM news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Vandana Singh

    Why Is Neuronetics Stock Soaring Monday?

  • Full Transcript: Neuronetics Q1 2026 Earnings Call

  • Caroline Ryan

    Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan

  • Press releasePRNewswire

    Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business

  • Press releaseBusiness Wire

    Diality Appoints Peter Donato as Chief Financial Officer

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Neuronetics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.